· Clinical research
Junshi Biosciences reports primary endpoint results in the NEOTORCH study
Junshi Biosciences reported final-analysis results for perioperative toripalimab with chemotherapy in resectable stage II or III non-small cell lung cancer.
In the combined stage II and III population, event-free survival and the major pathological response rate met the prespecified thresholds. The company subsequently presented full results at the ESMO Congress in October.
Read the full company release